ADMA FY 2024 Earnings — ADMA Biologics, Inc. Revenue & Financial Results | Market Cap Arena

ADMAADMA Biologics, Inc.

$4B

FY 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$426M+65.2% YoY

Gross Profit

$220M51.5% margin

Operating Income

$139M32.6% margin

Net Income

$198M46.4% margin

EPS (Diluted)

$0.81

Cash Flow

Operating Cash Flow

$119M

Free Cash Flow

$110M

Stock-Based Comp.

$14M

Balance Sheet

Total Assets

$489M

Total Liabilities

$140M

Stockholders' Equity

$349M

Cash & Equivalents

$103M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$426M	$258M	+65.2%
Gross Profit	$220M	$89M	+146.8%
Operating Income	$139M	$22M	+542.5%
Net Income	$198M	-$28M	+800.0%